{"transactions":[{"id":1545398,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T16:12:39.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":12.06,"expiration_date":"2029-01-11","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950170-24-042600","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095017024042600/ownership.xml","form_type":"4"}},{"id":1545397,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T16:12:39.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":13.35,"expiration_date":"2029-05-14","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0000950170-24-042600","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095017024042600/ownership.xml","form_type":"4"}},{"id":1545396,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T16:12:39.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":38000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":13.35,"expiration_date":"2029-05-14","underlying":"Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0000950170-24-042600","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095017024042600/ownership.xml","form_type":"4"}},{"id":1545395,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T16:12:39.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16806,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":20.37,"expiration_date":"2030-05-19","underlying":"Common Stock","underlying_shares":16806},"source":{"system":"sec-edgar","filing":"0000950170-24-042600","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095017024042600/ownership.xml","form_type":"4"}},{"id":1545394,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T16:12:39.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19619,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":17.24,"expiration_date":"2031-06-07","underlying":"Common Stock","underlying_shares":19619},"source":{"system":"sec-edgar","filing":"0000950170-24-042600","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095017024042600/ownership.xml","form_type":"4"}},{"id":1545393,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T16:12:39.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24222,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":13.35,"expiration_date":"2032-05-17","underlying":"Common Stock","underlying_shares":24222},"source":{"system":"sec-edgar","filing":"0000950170-24-042600","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095017024042600/ownership.xml","form_type":"4"}},{"id":1545392,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T16:12:39.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":78407,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":3.69,"expiration_date":"2033-05-09","underlying":"Common Stock","underlying_shares":78407},"source":{"system":"sec-edgar","filing":"0000950170-24-042600","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095017024042600/ownership.xml","form_type":"4"}},{"id":1545391,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T16:12:39.000Z","date":"2024-04-05","kind":"other","planned":false,"acquired":false,"shares":7000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-042600","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095017024042600/ownership.xml","form_type":"4"}},{"id":1894935,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-12T17:51:51.000Z","date":"2023-05-10","kind":"grant","planned":false,"acquired":true,"shares":78407,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in four (4) approximately equal quarterly installments, such that the option shall be fully vested on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day prior to the Issuer's next annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date."}],"balance_after":78407,"derivative":{"exercise_price":3.69,"expiration_date":"2033-05-09","underlying":"Common Stock","underlying_shares":78407},"source":{"system":"sec-edgar","filing":"0001209191-23-029187","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000120919123029187/doc4.xml","form_type":"4"}},{"id":2261673,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-20T18:23:30.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":24222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in four (4) approximately equal quarterly installments, such that the option shall be fully vested on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day prior to the Issuer's next annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date."}],"balance_after":24222,"derivative":{"exercise_price":13.35,"expiration_date":"2032-05-17","underlying":"Common Stock","underlying_shares":24222},"source":{"system":"sec-edgar","filing":"0001209191-22-031134","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000120919122031134/doc4.xml","form_type":"4"}},{"id":2673799,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-10T17:36:14.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":19619,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in four (4) approximately equal quarterly installments, such that the option shall be fully vested on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day prior to the Issuer's next annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date."}],"balance_after":19619,"derivative":{"exercise_price":17.24,"expiration_date":"2031-06-07","underlying":"Common Stock","underlying_shares":19619},"source":{"system":"sec-edgar","filing":"0001209191-21-039587","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000120919121039587/doc4.xml","form_type":"4"}},{"id":2892208,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-01-28T19:04:04.000Z","date":"2021-01-26","kind":"disposition_to_issuer","acquired":false,"shares":4526,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each restricted stock unit that was outstanding immediately prior to the Effective Time was cancelled and automatically converted into 1.85 shares of Parent common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each restricted stock unit that was outstanding immediately prior to the Effective Time was cancelled and automatically converted into 1.85 shares of Parent common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, each restricted stock unit that was outstanding immediately prior to the Effective Time was cancelled and automatically converted into 1.85 shares of Parent common stock."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4526},"source":{"system":"sec-edgar","filing":"0000899243-21-003642","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924321003642/doc4.xml","form_type":"4"}},{"id":2892207,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-28T19:04:04.000Z","date":"2021-01-26","kind":"disposition_to_issuer","acquired":false,"shares":21447,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the \"Merger Agreement\"), by and among the Issuer, BridgeBio Pharma, Inc. (\"Parent\"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub\"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub II\"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued From Footnote 1) The option vests in three annual installments after August 6, 2020.  At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85.  Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the \"Merger Agreement\"), by and among the Issuer, BridgeBio Pharma, Inc. (\"Parent\"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub\"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub II\"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued From Footnote 1) The option vests in three annual installments after August 6, 2020.  At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85.  Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":41.42,"expiration_date":"2030-08-05","underlying":"Common Stock","underlying_shares":21447},"source":{"system":"sec-edgar","filing":"0000899243-21-003642","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924321003642/doc4.xml","form_type":"4"}},{"id":3063604,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-10T19:26:45.000Z","date":"2020-08-06","kind":"grant","acquired":true,"shares":21447,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option shall vest in three annual installments after the date of grant, subject to the Reporting Person's continued service on the Issuer's board of directors as of each vesting date."}],"balance_after":21447,"derivative":{"exercise_price":41.42,"expiration_date":"2030-08-05","underlying":"Common Stock","underlying_shares":21447},"source":{"system":"sec-edgar","filing":"0000899243-20-021958","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320021958/doc4.xml","form_type":"4"}},{"id":3063603,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-08-10T19:26:45.000Z","date":"2020-08-06","kind":"grant","acquired":true,"shares":4526,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Common Stock underlying the RSUs vest in three annual installments after the date of grant, subject to the Reporting Person's continued service on the Issuer's board of directors as of each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares of Common Stock underlying the RSUs vest in three annual installments after the date of grant, subject to the Reporting Person's continued service on the Issuer's board of directors as of each vesting date."}],"balance_after":4526,"derivative":{"underlying":"Common Stock","underlying_shares":4526},"source":{"system":"sec-edgar","filing":"0000899243-20-021958","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320021958/doc4.xml","form_type":"4"}},{"id":3137034,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-22T18:47:49.000Z","date":"2020-05-20","kind":"grant","acquired":true,"shares":16806,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in four (4) approximately equal quarterly installments, such that the option shall be fully vested on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day prior to the next Issuer's annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date."}],"balance_after":16806,"derivative":{"exercise_price":20.37,"expiration_date":"2030-05-19","underlying":"Common Stock","underlying_shares":16806},"source":{"system":"sec-edgar","filing":"0001209191-20-031871","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000120919120031871/doc4.xml","form_type":"4"}},{"id":3520641,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-17T11:45:36.000Z","date":"2019-05-15","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Issued pursuant to the Amended and Restated 2018 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option shall vest in four (4) approximately equal quarterly installments, such that the option shall be fully vested on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day prior to the next Issuer's annual stockholder meeting held after the effective date of the initial public offering, subject to the Reporting Person's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date."}],"balance_after":24000,"derivative":{"exercise_price":13.35,"expiration_date":"2019-05-14","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-19-030719","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000120919119030719/doc4.xml","form_type":"4"}},{"id":3520640,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-17T11:45:36.000Z","date":"2019-05-15","kind":"grant","acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Issued pursuant to the Amended and Restated 2018 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest over a three-year period, with 1/3rd of the shares vesting on August 10, 2019, and the remainder vesting in eight (8) equal quarterly installments thereafter, such that the option shall be fully vested on August 10, 2021, subject to the Reporting Person's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date."}],"balance_after":38000,"derivative":{"exercise_price":13.35,"expiration_date":"2029-05-14","underlying":"Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001209191-19-030719","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000120919119030719/doc4.xml","form_type":"4"}},{"id":3558373,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-10T11:25:03.000Z","date":"2019-04-08","kind":"purchase","acquired":true,"shares":7000,"price":16,"value":112000.0,"ownership":{"direct":true},"balance_after":7000,"source":{"system":"sec-edgar","filing":"0001209191-19-024200","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000120919119024200/doc4.xml","form_type":"4"}},{"id":3628704,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2019-02-28T02:10:17.000Z","date":"2019-02-27","kind":"exercise","acquired":false,"shares":6666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This non-qualified stock option is part of an option award granted on August 9, 2012. The ordinary shares subject to the option award vested over 4 years from the vesting commencement date of August 9, 2012, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016."}],"balance_after":28671,"derivative":{"exercise_price":46.83,"expiration_date":"2022-08-08","underlying":"Ordinary Shares","underlying_shares":6666},"source":{"system":"sec-edgar","filing":"0001765581-19-000015","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000176558119000015/edgardoc.xml","form_type":"4"}},{"id":3628703,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Ordinary Shares","published_at":"2019-02-28T02:10:17.000Z","date":"2019-02-27","kind":"sale","acquired":false,"shares":6666,"price":140,"value":933240.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":39738,"source":{"system":"sec-edgar","filing":"0001765581-19-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000176558119000015/edgardoc.xml","form_type":"4"}},{"id":3628702,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Ordinary Shares","published_at":"2019-02-28T02:10:17.000Z","date":"2019-02-27","kind":"exercise","acquired":true,"shares":6666,"price":46.83,"value":312168.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":46404,"source":{"system":"sec-edgar","filing":"0001765581-19-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000176558119000015/edgardoc.xml","form_type":"4"}},{"id":3628701,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Ordinary Shares","published_at":"2019-02-28T02:10:17.000Z","date":"2019-02-26","kind":"tax_withholding","acquired":false,"shares":663,"price":127.76,"value":84704.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units."}],"balance_after":39738,"source":{"system":"sec-edgar","filing":"0001765581-19-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000176558119000015/edgardoc.xml","form_type":"4"}},{"id":3628700,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Ordinary Shares","published_at":"2019-02-28T02:10:17.000Z","date":"2019-02-25","kind":"tax_withholding","acquired":false,"shares":783,"price":126.25,"value":98853.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units."}],"balance_after":40401,"source":{"system":"sec-edgar","filing":"0001765581-19-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000176558119000015/edgardoc.xml","form_type":"4"}},{"id":3730469,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2018-12-14T23:04:45.000Z","date":"2018-12-14","kind":"exercise","acquired":false,"shares":3295,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This non-qualified stock option is part of an option award granted on August 9, 2012. The ordinary shares subject to the option award vested over 4 years from the vesting commencement date of August 9, 2012, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016."}],"balance_after":35337,"derivative":{"exercise_price":46.83,"expiration_date":"2022-08-08","underlying":"Ordinary Shares","underlying_shares":3295},"source":{"system":"sec-edgar","filing":"0001232524-18-000202","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252418000202/edgardoc.xml","form_type":"4"}},{"id":3730468,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Ordinary Shares","published_at":"2018-12-14T23:04:45.000Z","date":"2018-12-14","kind":"sale","acquired":false,"shares":39,"price":140.21,"value":5468.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":41184,"source":{"system":"sec-edgar","filing":"0001232524-18-000202","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252418000202/edgardoc.xml","form_type":"4"}},{"id":3730467,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Ordinary Shares","published_at":"2018-12-14T23:04:45.000Z","date":"2018-12-14","kind":"sale","acquired":false,"shares":3295,"price":140.21,"value":461991.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":41223,"source":{"system":"sec-edgar","filing":"0001232524-18-000202","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252418000202/edgardoc.xml","form_type":"4"}},{"id":3730466,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Ordinary Shares","published_at":"2018-12-14T23:04:45.000Z","date":"2018-12-14","kind":"exercise","acquired":true,"shares":3295,"price":46.83,"value":154304.85,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 173 ordinary shares acquired on May 31, 2018 and 72 shares acquired on November 30, 2018 under a Section 423 Employee Stock Purchase Plan."}],"balance_after":44518,"source":{"system":"sec-edgar","filing":"0001232524-18-000202","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252418000202/edgardoc.xml","form_type":"4"}},{"id":3932637,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2018-05-15T20:41:55.000Z","date":"2018-05-14","kind":"exercise","acquired":false,"shares":1691,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This incentive stock option is part of an option award granted on March 5, 2013. The ordinary shares subject to the option award vested over 4 years from the vesting commencement date of March 5, 2013, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of March 5, 2017."}],"balance_after":0,"derivative":{"exercise_price":59.13,"expiration_date":"2023-03-04","underlying":"Ordinary Shares","underlying_shares":1691},"source":{"system":"sec-edgar","filing":"0001232524-18-000099","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252418000099/edgardoc.xml","form_type":"4"}},{"id":3932636,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2018-05-15T20:41:55.000Z","date":"2018-05-14","kind":"exercise","acquired":false,"shares":8540,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This incentive stock option is part of an option award granted on August 9, 2012. The ordinary shares subject to the option award vested over 4 years from the vesting commencement date of August 9, 2012, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016."}],"balance_after":0,"derivative":{"exercise_price":46.83,"expiration_date":"2022-08-08","underlying":"Ordinary Shares","underlying_shares":8540},"source":{"system":"sec-edgar","filing":"0001232524-18-000099","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252418000099/edgardoc.xml","form_type":"4"}},{"id":3932635,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Ordinary Shares","published_at":"2018-05-15T20:41:55.000Z","date":"2018-05-14","kind":"exercise","acquired":true,"shares":1691,"price":59.13,"value":99988.83,"ownership":{"direct":true},"balance_after":40978,"source":{"system":"sec-edgar","filing":"0001232524-18-000099","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252418000099/edgardoc.xml","form_type":"4"}},{"id":3932634,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Ordinary Shares","published_at":"2018-05-15T20:41:55.000Z","date":"2018-05-14","kind":"exercise","acquired":true,"shares":8540,"price":46.83,"value":399928.2,"ownership":{"direct":true},"balance_after":39287,"source":{"system":"sec-edgar","filing":"0001232524-18-000099","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252418000099/edgardoc.xml","form_type":"4"}},{"id":3932633,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Ordinary Shares","published_at":"2018-05-15T20:41:55.000Z","date":"2018-05-11","kind":"sale","acquired":false,"shares":7500,"price":165,"value":1237500.0,"ownership":{"direct":true},"balance_after":30747,"source":{"system":"sec-edgar","filing":"0001232524-18-000099","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252418000099/edgardoc.xml","form_type":"4"}},{"id":4007843,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Ordinary Shares","published_at":"2018-03-07T21:12:22.000Z","date":"2018-03-05","kind":"tax_withholding","acquired":false,"shares":1239,"price":143.39,"value":177660.21,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units."}],"balance_after":38247,"source":{"system":"sec-edgar","filing":"0001232524-18-000065","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252418000065/edgardoc.xml","form_type":"4"}},{"id":4014370,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2018-03-05T21:27:57.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":22790,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 1, 2018, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":22790,"derivative":{"exercise_price":140.67,"expiration_date":"2028-02-29","underlying":"Ordinary Shares","underlying_shares":22790},"source":{"system":"sec-edgar","filing":"0001232524-18-000043","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252418000043/edgardoc.xml","form_type":"4"}},{"id":4014369,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2018-03-05T21:27:57.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":710,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 1, 2018, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":710,"derivative":{"exercise_price":140.67,"expiration_date":"2028-02-29","underlying":"Ordinary Shares","underlying_shares":710},"source":{"system":"sec-edgar","filing":"0001232524-18-000043","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252418000043/edgardoc.xml","form_type":"4"}},{"id":4014368,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Ordinary Shares","published_at":"2018-03-05T21:27:57.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":9400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2018, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years."}],"balance_after":39486,"source":{"system":"sec-edgar","filing":"0001232524-18-000043","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252418000043/edgardoc.xml","form_type":"4"}},{"id":4026776,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Ordinary Shares","published_at":"2018-02-28T22:25:05.000Z","date":"2018-02-27","kind":"tax_withholding","acquired":false,"shares":864,"price":143.8,"value":124243.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units."}],"balance_after":30086,"source":{"system":"sec-edgar","filing":"0001232524-18-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252418000026/edgardoc.xml","form_type":"4"}},{"id":4026775,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Ordinary Shares","published_at":"2018-02-28T22:25:05.000Z","date":"2018-02-26","kind":"tax_withholding","acquired":false,"shares":1445,"price":147.44,"value":213050.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 73 ordinary shares acquired on November 30, 2017 under a Section 423 Employee Stock Purchase Plan."}],"balance_after":30950,"source":{"system":"sec-edgar","filing":"0001232524-18-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252418000026/edgardoc.xml","form_type":"4"}},{"id":4253158,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Ordinary Shares","published_at":"2017-07-21T21:47:09.000Z","date":"2017-07-20","kind":"sale","acquired":false,"shares":4580,"price":160,"value":732800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":32322,"source":{"system":"sec-edgar","filing":"0001544589-17-000010","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000154458917000010/edgardoc.xml","form_type":"4"}},{"id":4272468,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Ordinary Shares","published_at":"2017-06-26T23:19:00.000Z","date":"2017-06-23","kind":"sale","acquired":false,"shares":420,"price":160,"value":67200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 173 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2017."}],"balance_after":36902,"source":{"system":"sec-edgar","filing":"0001544589-17-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000154458917000008/edgardoc.xml","form_type":"4"}},{"id":4326463,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Ordinary Shares","published_at":"2017-05-10T22:00:22.000Z","date":"2017-05-09","kind":"sale","acquired":false,"shares":2500,"price":160,"value":400000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":37149,"source":{"system":"sec-edgar","filing":"0001544589-17-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000154458917000006/edgardoc.xml","form_type":"4"}},{"id":4341954,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Ordinary Shares","published_at":"2017-04-28T22:26:47.000Z","date":"2017-04-27","kind":"sale","acquired":false,"shares":2500,"price":160,"value":400000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":39649,"source":{"system":"sec-edgar","filing":"0001544589-17-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000154458917000004/edgardoc.xml","form_type":"4"}},{"id":4394571,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Ordinary Shares","published_at":"2017-03-08T23:26:40.000Z","date":"2017-03-06","kind":"tax_withholding","acquired":false,"shares":2087,"price":132.81,"value":277174.47,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units."}],"balance_after":42149,"source":{"system":"sec-edgar","filing":"0001232524-17-000077","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252417000077/primary_doc.xml","form_type":"4"}},{"id":4400075,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-03-07T00:54:36.000Z","date":"2017-03-02","kind":"grant","acquired":true,"shares":24266,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 2, 2017, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":24266,"derivative":{"exercise_price":136.18,"expiration_date":"2027-03-01","underlying":"Ordinary Shares","underlying_shares":24266},"source":{"system":"sec-edgar","filing":"0001232524-17-000065","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252417000065/primary_doc.xml","form_type":"4"}},{"id":4400074,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2017-03-07T00:54:36.000Z","date":"2017-03-02","kind":"grant","acquired":true,"shares":734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 2, 2017, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":734,"derivative":{"exercise_price":136.18,"expiration_date":"2027-03-01","underlying":"Ordinary Shares","underlying_shares":734},"source":{"system":"sec-edgar","filing":"0001232524-17-000065","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252417000065/primary_doc.xml","form_type":"4"}},{"id":4400073,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Ordinary Shares","published_at":"2017-03-07T00:54:36.000Z","date":"2017-03-02","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2017, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years."}],"balance_after":44236,"source":{"system":"sec-edgar","filing":"0001232524-17-000065","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252417000065/primary_doc.xml","form_type":"4"}},{"id":4413621,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":92142,"kind":"person","name":"Hooper Suzanne Sawochka","position":1,"cik":"0001544589","reported_name":"Hooper Suzanne Sawochka","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Ordinary Shares","published_at":"2017-03-01T22:13:22.000Z","date":"2017-02-27","kind":"tax_withholding","acquired":false,"shares":2511,"price":136.97,"value":343931.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 48 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2016."}],"balance_after":69236,"source":{"system":"sec-edgar","filing":"0001232524-17-000034","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252417000034/edgardoc.xml","form_type":"4"}}]}